Grifols, ES0171996087

Grifols stock reports 28.7 percent H1 profit growth

Published on 10/04/2026 at 20:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock follows a 28.7 percent H1 profit increase to EUR 227 million, while free cash flow reached EUR 91 million. Guidance remains intact.

Isometrische 3D-Grafik der Plasma-Wertschöpfungskette von Spende bis Medikament — Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) closed at EUR 9.60 on BME on October 1, 2026, up 2.56 percent, as the plasma therapeutics group carried stronger first-half earnings into the market. The company reported H1 2026 net profit of EUR 227 million, a 28.7 percent year-over-year increase, according to Grifols on its investor page.

Profit rises 28.7 percent

H1 revenue reached EUR 3.574 billion, up 2.6 percent at constant currency, with Biopharma revenue increasing 5.4 percent at constant currency. The result points to a growth mix led by the core plasma-derived medicines business rather than by a broad expansion across every operating line.

Adjusted EBITDA totaled EUR 854 million in the first half, up 2.4 percent year over year at constant currency, while the adjusted EBITDA margin reached 23.9 percent. The margin figure gives investors a more useful operating checkpoint than revenue alone because it captures the benefit of efficiency measures alongside sales growth.

Cash flow guidance stays intact

Free cash flow before mergers and acquisitions reached EUR 91 million in H1 2026, an improvement of EUR 103 million from the prior-year period, according to Quartr on October 1, 2026. Management maintained full-year free cash flow guidance of EUR 500 million to EUR 575 million before M&A.

Net leverage stood at 4.2 times in the H1 summary, leaving debt reduction and cash conversion as important measures for the second half. The company also highlighted immunoglobulin demand, the Egypt plasma ramp-up and disciplined cost management as supports for the 2026 outlook.

Canada remains a regulatory risk

The earnings progress is balanced by a regulatory issue in Canada. Reuters reported on September 24, 2026, that Health Canada suspended the license of a Winnipeg plasma collection facility, while Grifols said the action would not affect ongoing operations and that it was working on a reopening plan.

BME close frames the stock

Grifols stock closed at EUR 9.60 on BME on October 1, 2026, with a daily gain of 2.56 percent. The market is therefore weighing improved profit and cash flow against execution demands in plasma collection, debt management and the confirmed full-year guidance.